Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention.
Jang JY, Ga-In Y, Jongwha A, Bae JS, Yun-Ho C, Kang MG, Koh JS, Jeong YH, Sang Yeup L, Byeong-Keuk K, Hyung Joon J, Do-Sun L, Chang K, Bin Song Y, Sung Gyun A, Suh JW, Jung Rae C, Kim HS, Kim MHH, Shin ES, Park Y.
Jang JY, et al. Among authors: kim hs.
Thromb Haemost. 2024 Dec 10. doi: 10.1055/a-2499-5458. Online ahead of print.
Thromb Haemost. 2024.
PMID: 39657950
Clinical Trial.